{"id":"NCT02047734","sponsor":"Celgene","briefTitle":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","officialTitle":"A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-03","primaryCompletion":"2017-03-27","completion":"2017-04-13","firstPosted":"2014-01-28","resultsPosted":"2021-02-11","lastUpdate":"2021-02-11"},"enrollment":1320,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ozanimod","otherNames":["RPC1063","Zeposia®"]},{"type":"DRUG","name":"Ozanimod placebo","otherNames":[]},{"type":"DRUG","name":"Interferon beta-1a","otherNames":["Avonex"]},{"type":"DRUG","name":"Interferon beta-1a placebo","otherNames":[]}],"arms":[{"label":"Ozanimod 0.5 mg","type":"EXPERIMENTAL"},{"label":"Ozanimod1 mg","type":"EXPERIMENTAL"},{"label":"Interferon β-1a","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record.\n\nThe primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).","primaryOutcome":{"measure":"Adjusted Annualized Relapse Rate (ARR) at the End of Month 24","timeFrame":"At the end of month 24","effectByArm":[{"arm":"Interferon Beta-1a","deltaMin":0.276,"sd":null},{"arm":"Ozanimod 0.5 mg","deltaMin":0.218,"sd":null},{"arm":"Ozanimod 1 mg","deltaMin":0.172,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0167"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":299,"countries":["United States","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Croatia","Georgia","Greece","Hungary","Italy","Moldova","Poland","Romania","Russia","Serbia","Slovakia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["31492652","40462564"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":440},"commonTop":["Influenza Like Illness","Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Orthostatic Hypotension"]}}